A clinical study to investigate the effects of dapagliflozin on heart work, heart nutrient uptake, and heart muscle efficiency in type 2 diabetes patients

Trial Identifier: D1690C00063
Sponsor: AstraZeneca
NCTID:: NCT03387683
Start Date: February 2018
Primary Completion Date: March 2019
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Finnish Translation
Swedish Translation

Trial Locations

Country Location
Finland Turku, Finland, 20520
Sweden Uppsala, Sweden, SE-751 85